Gilead inks deal with Canadian antibody discovery firm AbCellera

pharmafile | June 14, 2019 | News story | Medical Communications AbCellera, Gilead, monoclonal antibodies, pharma 

Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.

The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.

Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.

Using a sutie of proprietary technologies, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead.

Louis Goss

Related Content

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …


‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Latest content